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Abstract
Background: DNA methylation is a well-studied epigenetic mark that is frequently altered in diseases such as
cancer, where specific changes are known to reflect the type and severity of the disease. Therefore, there is a
growing interest in assessing the clinical utility of DNA methylation as a biomarker for diagnosing disease and
guiding treatment. The development of an accurate loci-specific methylation assay, suitable for use on low-input
clinical material, is crucial for advancing DNA methylation biomarkers into a clinical setting. A targeted multiplex
bisulphite PCR sequencing approach meets these needs by allowing multiple DNA methylated regions to be
interrogated simultaneously in one experiment on limited clinical material.
Results: Here, we provide an updated protocol and recommendations for multiplex bisulphite PCR sequencing
(MBPS) assays for target DNA methylation analysis. We describe additional steps to improve performance and
reliability: (1) pre-sequencing PCR optimisation which includes assessing the optimal PCR cycling temperature and
primer concentration and (2) post-sequencing PCR optimisation to achieve uniform coverage of each amplicon. We
use a gradient of methylated controls to demonstrate how PCR bias can be assessed and corrected. Methylated
controls also allow assessment of the sensitivity of methylation detection for each amplicon. Here, we show that
the MBPS assay can amplify as little as 0.625 ng starting DNA and can detect methylation differences of 1% with a
sequencing coverage of 1000 reads. Furthermore, the multiplex bisulphite PCR assay can comprehensively
interrogate multiple regions on 1–5 ng of formalin-fixed paraffin-embedded DNA or circulating cell-free DNA.
Conclusions: The MBPS assay is a valuable approach for assessing methylated DNA regions in clinical samples with
limited material. The optimisation and additional quality control steps described here improve the performance and
reliability of this method, advancing it towards potential clinical applications in biomarker studies.
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Introduction
DNA cytosine methylation is a key epigenetic mark asso-
ciated with gene regulation and function [1, 2]. DNA
methylation can be modified by environmental expo-
sures [3, 4] and is associated with a wide range of dis-
eases including developmental pathologies [5] and
cancer [6–8], where methylation changes are particularly
pronounced. The growing body of public DNA methyla-
tion datasets for a variety of cancer types [9–11] pro-
vides data to enable discovery of novel clinical
biomarkers for both early detection of tumours and
monitoring of minimal residual disease [12–14]. The use
of DNA methylation as a clinical biomarker is made
feasible by the fact that it is highly stable and retained
during long-term storage of clinical material, including
formalin-fixed paraffin-embedded tissue (FFPET).
The first stage of DNA methylation biomarker discovery
is usually to screen the genome for methylation changes
associated with the clinical phenotype of interest. These
studies employ epigenome-wide methods that generate
data at single-base resolution, such as whole-genome
bisulphite sequencing (WGBS) [15–18] and microarray
technologies [19, 20]. Following analysis, DNA methyla-
tion differences are frequently observed between disease
groups, often occurring across adjacent CpG sites, termed
differentially methylated regions (DMRs) [21]. Translation
of these findings into the clinic requires further screening
and validation of the DMRs in independent retrospective
and prospective cohorts to assess their clinical value as a
biomarker for the phenotype of interest. This necessitates
the development of DNA methylation assays that are
compatible with, and easily integrated into, routine clinical
use, thus needing to be cost-effective, scalable and repro-
ducible [22, 23]. Additionally, clinical samples are often
limited; therefore, the method needs to produce accurate
methylation data from low and degraded DNA sample in-
puts. To this end, it has been previously shown that loci-
specific PCR-based methods, such as targeted bisulphite
PCR sequencing, exhibit the most consistent performance
on low-input clinical samples compared to other DNA
methylation assays, such as padlock probe-based or
microdroplet-based enrichment techniques [22]. Further-
more, PCR primers can be multiplexed to produce mul-
tiple amplicons in a single bisulphite PCR reaction. This
allows the interrogation and generation of methylation
data across many regions concurrently in one experiment.
Together, this establishes multiplex bisulphite PCR se-
quencing (MBPS) as a technology ready for widespread
biomarker development and clinical use.
An MBPS assay that is able to deliver robust methyla-
tion data from FFPET clinical DNA has previously been
developed and published [23]. Here, we provide an im-
proved protocol and additional optimisation steps for
this methodology. We perform technical comparisons
between multiplex bisulphite PCR sequencing and the
WGBS platform. We comprehensively evaluate its utility
in interrogating multiple genomic regions simultan-
eously, in minimal amounts of FFPET clinical DNA and
in patient-derived circulating cell-free DNA (cfDNA). Fi-
nally, we demonstrate the ability of the MBPS assay to
measure intra- and inter-sample methylation variability
through assessment of epigenetic heterogeneity.
Results
Previously, we performed DNA methylation biomarker
discovery studies using whole-genome methylation pro-
filing of prostate cancer [24] and breast cancer [25]. The
DMRs identified in these studies form the basis of the
biomarker panels of multiplex PCR primers used in the
current work. We designed two panels of multiplex
primers each for prostate cancer—63 DMRs (panel 1:
n = 31 and panel 2: n = 32 PCR amplicons in each
panel)—and for breast cancer—33 DMRs (panel 1: n =
17 and panel 2: n = 16 PCR amplicons in each panel)
(see the “Material and methods”). We use these panels
to demonstrate the steps required for panel optimisation
for MBPS and to evaluate the performance of the assay,
as described below.
Overview of multiplex bisulphite PCR sequencing protocol
An overview of the MBPS protocol is shown in Fig. 1,
comprising the following key steps: (1) primer design: de-
sign primers for the user’s genomic regions of interest. For
this, we recommend the multiplex-friendly primer design
software PrimerSuite [26]. (2) Bisulphite conversion: per-
form bisulphite conversion of DNA. This converts
unmethylated cytosines into uracils, thus allowing methyl-
ated and non-methylated CpGs to be distinguished follow-
ing PCR and sequencing. Whilst optimising the assay, it is
advised to use ‘test’ DNA rather than DNA from precious
clinical samples. (3) Optimisation: perform PCR optimisa-
tion to ensure that all of the primers are amplifying
bisulphite-converted DNA as expected. Parameters in-
clude annealing temperature, primer concentration and
DNA input amount. Optimisation is performed first with
individual primer pairs (‘singleplex PCR’) and then with
multiplex panels of pooled primer pairs. (4) Multiplex
bisulphite PCR: perform multiplex bisulphite PCR on
bisulphite-treated DNA of the samples deemed necessary
to assess the performance of the method after sequencing.
(5–7) Library preparation, sequencing and bioinformatics:
perform library preparation, purification and quantifica-
tion, followed by sequencing and bioinformatic processing
and analysis. This can be performed using our dedicated
bioinformatic mapping and QC pipeline, called MethPanel
[27], which includes data visualization using the shinyApp
(https://github.com/thinhong/MethPanel). The sequen-
cing results may reveal that further optimisation is needed,
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in which case post-sequencing multiplex bisulphite PCR
optimisation (as described below) can be conducted and
sequencing repeated (steps 4–7) to confirm the good qual-
ity of sequencing data, before applying the method to clin-
ical samples and appropriate controls. A detailed version
of the flow-diagram (Additional file 1: Figure S1) and a
step-by-step protocol (Additional file 2) is provided in the
supplementary materials.
Optimisation of panels for multiplex bisulphite PCR
sequencing
Pre-sequencing PCR optimisation
PCR conditions need to be optimised to ensure good
amplification of target regions using each individual pri-
mer pair in a panel. Bisulphite-treated DNA is PCR-
amplified for each primer pair as a singleplex PCR to
verify primer specificity and minimal primer dimer for-
mation. For example, during singleplex PCR optimisa-
tion of the breast cancer panels on ‘test’ DNA, we saw
robust, specific amplification from all individual primer
pairs, with only one primer pair (#31) showing a slightly
reduced yield of PCR product (Fig. 2a). Next, the
primers are pooled into their respective multiplex
panels, and the optimal primer concentration and PCR
cycling temperature are determined. Here, we show that
for the breast panels, a concentration of 20 μM for each
primer pool yields excessive primer dimer relative to
lower primer concentrations (1, 5 and 10 μM) whilst a
concentration of 1 μM did not amplify the DNA (Fig.
2b). Temperatures of 55 °C and 56 °C both yield robust
Fig. 1 Flow diagram of the multiplex PCR bisulphite sequencing assay. A flow diagram highlighting the key steps in the multiplex PCR bisulphite
sequencing assay. A detailed step-by-step protocol is included in Supplementary Information (Additional file 2)
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PCR amplification. Thus, we used a temperature of
56 °C and a primer concentration of 10 μM in all subse-
quent PCRs with the breast cancer panels. As these as-
says were to be performed on DNA from limited breast
cancer samples, a titration of DNA input concentrations
(10 ng to 0.625 ng per multiplex PCR) was run to assess
the minimum amount of DNA required for amplifying
enough DNA for library preparation (Fig. 2c). Both
breast cancer panels successfully amplified as little as
0.625 ng input DNA. Similar images for the prostate
cancer panels are supplied in the supplementary mate-
rials (Additional file 3: Figure S2).
Post-sequencing quality control and optimisation
Following library preparation, DNA sequencing and ana-
lysis, further refinement and optimisation of the MBPS
assay may need to be performed post-sequencing, as de-
scribed below:
Sequencing coverage An initial quality control step is
to compare the sequencing coverage of different ampli-
cons to confirm uniform amplification. This is important
because with such a large number of primers competing
to hybridise and amplify DNA in one PCR, there are
likely to be primers that fail to amplify completely (i.e.
amplicons that have very low or no coverage) or primers
that favourably amplify over others. This may occur des-
pite using the multiplex-specific primer design software
and pre-sequencing PCR optimisation. These deviating
primers can either be (1) removed from future multiplex
PCR reactions, (2) redesigned or (3) potentially ‘rescued’.
For example, we observed that the second prostate
cancer multiplex panel had a number (n = 13/32) of
dropouts (i.e. coverage < 100) (Fig. 3a). We took these
13 ‘failed’ primers (Fig. 3a, grey boxes with purple back-
ground) and pooled them together as a separate, ‘new’
multiplex panel. We then performed the optimisation of
the multiplex PCR (primer concentration and
temperature), observing that with a 3-fold increase in
primer concentration (as compared to the original two
prostate panels), we were able to amplify these regions
in a separate multiplex PCR reaction. Sequencing of this
new sub-panel showed that all the amplicons now had
sufficient sequencing coverage for analysis, with the ex-
ception of amplicon #30 (Fig. 3a, blue boxes with purple
background). An alternative way to improve the cover-
age of individual amplicons is to leave primers grouped
with the primers from their original panels and adjust
individual primer concentrations. This can be done by
either increasing primer concentration of low-coverage
amplicons or by decreasing the primer concentration of
the high-coverage amplicons. We performed a primer
concentration adjustment on the breast cancer panels,
halving the concentration of primers that had an over-
representation in sequencing coverage (Fig. 3b, shaded
in orange), whilst doubling the concentration of those
with low coverage (Fig. 3b, shaded in green). Together,
this improved the balance of the coverage between the
amplicons (Fig. 3b, as observable in the top panel
through the difference between grey versus blue boxes
and the barplot in the bottom panel).
PCR bias A further critical post-sequencing quality con-
trol step is the assessment of PCR bias as this can affect
Fig. 2 Pre-sequencing optimisation of multiplex PCR primers. a PCR products of singleplex amplification of 33 individual primer pairs from the
breast cancer panels run on 2% agarose gel. The gels show the specificity of all the primer pairs and PCR products of the correct size (100–130
bp) with minimal primer dimer formation. (−) no template; (+) bisulphite-treated test DNA template (10 ng); (L) 100 bp DNA Ladder. b Singleplex
primers were pooled into their respective multiplex panels, and the outcome of multiplex PCR reactions is shown at different primer
concentrations (20 μM, 10 μM, 5 μM and 1 μM) and at different annealing temperatures (55 °C, 56 °C and 57 °C). c PCR products from the
multiplex panels testing DNA input amounts of 10 ng, 5 ng, 2.5 ng, 1.25 ng and 0.625 ng of bisulphite-treated control DNA; (+) test DNA; (−) no
template control
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the accuracy of estimation of the DNA methylation
levels. To aid in the accurate quantitation of methylation
levels, we included fully methylated and unmethylated
control DNA (Zymo whole-genome amplified (WGA))
and a gradient of methylated-control DNA samples (e.g.
0%, 10%, 25%, 50%, 75%, 90%, 100%) to compare the ob-
served versus expected levels of methylation. Here, we
demonstrate calibration of DNA methylation levels using
the prostate cancer DNA samples. Using a previously
published formula [28, 29], we mathematically assessed
PCR bias (b) for each of our amplicons in the prostate
cancer panels (Fig. 3c (i), left panel for two example
amplicons). Next, we used b, the bias estimate, for each
amplicon in a regression (as described in Moskalev et al.
[29]) to correct the observed levels of methylation of the
gradient methylated-control DNA samples to closely re-
semble expected levels (Fig. 3c (ii), left panel). Having
verified the bias correction for each amplicon, we then
Fig. 3 Post-sequencing optimisation of multiplex bisulphite PCR assay. Boxplots show the range of sequencing coverage for individual amplicons
in the a prostate cancer and b breast cancer panels. Light grey and blue boxes are used to depict the sequencing coverage before and after
post-sequencing optimisation respectively. The purple background in a highlights the amplicons that originally failed sequencing (i.e. coverage <
100). The primers for these amplicons were pooled and re-amplified in an individual third multiplex panel. b For the breast cancer panels—the
green background indicates the amplicons that originally failed sequencing and the red background indicates the amplicons that were originally
amplified more than needed. For these primer pairs, primer concentrations were doubled (20 to 40 μM) or halved (20 to 10 μM) respectively to
achieve more uniform amplicon coverage. The corresponding barplot shows the change in sequencing coverage before and after post-
sequencing optimisation. c (i) PCR bias is introduced by PCR amplification of 2 example prostate amplicons (amplicon 46 and 35) using
methylated-control DNAs (0%, 10%, 25%, 50%, 75%, 90%, 100%). Observed methylation after amplification (y-axis) is plotted against expected
methylation levels (x-axis). Regression analysis was used to calculate a value of bias (b) as described by Warnecke et al. [28]. Red line = line of best
fit from the regression; dotted line = line of best fit if data was unbiased (i.e. b = 1). (ii) The result of PCR-bias correction by regression on the
methylated control DNA. The corrected methylation level (y-axis) is plotted against the expected methylation level (x-axis) showing that PCR bias
has been effectively corrected. (iii) Multiplex bisulphite PCR methylation values for four biological samples are corrected for PCR bias based on
the calculated bias value from (i) (light pink = LNCaP, light green = PrEC, violet = CAF, light brown = NPF). The corrected values are more similar
than the uncorrected values to the same samples profiled by WGBS (iv)
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used the same calculated bias estimates to perform PCR
bias correction of the cancer DNA samples (Fig. 3c (iii),
‘samples’) run in the same experiment as the
methylated-control DNA. We observed that following
correction, the multiplex data has a wider dynamic range
of methylation and is more similar to matched whole-
genome bisulphite methylation data from the same sam-
ples (Fig. 3c (iv), right panel). These bias plots and calcu-
lations can be performed using our recently developed
MethPanel shinyApp [27].
Sensitivity Another important quality control step is to
assess the sensitivity of each amplicon to determine how
much sequencing coverage is required to confidently
distinguish small changes in methylation levels. Utilising
the fully methylated and unmethylated control DNA, we
generated a gradient of methylated-control DNA sam-
ples (0%, 1% and 5%) and sequenced these across three
separate sequencing runs. By comparing observed levels
of DNA methylation (from sequencing, coverage > 161,
335 [amplicon 44] and coverage > 244,361 [amplicon
55]) to expected levels of methylation, we assessed the
technical sensitivity of the assay and found a significant
difference between 0%, 1% and 5% methylation levels
(Fig. 4a). By down-sampling at different sequence cover-
age levels, we found that the sensitivity of the assay im-
proves with increased coverage, for example, for
amplicons 44 and 55, we sensitively detected methyla-
tion differences of 1% with 1000x coverage and greater
(Fig. 4a, b). Additional representative amplicons are
shown in the supplementary materials (Additional file 4:
Figure S3).
Evaluation of the performance of multiplex bisulphite
PCR sequencing
In the following sections, we provide evidence about the
reproducibility of the method, its application to DNA
from different sample types and the level of detail about
DNA methylation that it can provide.
Methylation concordance between multiplex bisulphite PCR
and whole-genome bisulphite sequencing
One of the main applications for the MBPS assay is to
validate methylation changes identified from genome-
wide methylation analyses. It is therefore important that
the assay can provide accurate methylation data that is
consistent from the discovery phase platforms. To assess
this, we performed a DNA methylation comparison be-
tween WGBS and the MBPS assay data from the pros-
tate cancer panels, for matched data from normal
human prostate epithelial cells (PrEC), prostate cancer
epithelial cells (LNCaP), non-malignant prostate fibro-
blasts (NPF) and cancer-associated fibroblasts (CAF)
[24]. For the prostate cancer panels, the bias assessment
led us to correct the bias of 24/63 amplicons and we
used the bias-corrected data in our technical compari-
son. We first examined the correlation between absolute
methylation values of each CpG site (158 CpG sites
across 63 amplicons) as measured by the two platforms.
The correlation coefficients were highly significant in
each case (PrEC: r = 0.80, p < 2.2e−16; LNCaP: r = 0.91,
p < 2.2e−16; NPF: r = 0.84, p < 2.2e−16; CAF: r = 0.95,
p < 2.2e−16), but not completely concordant with WGBS
data (Additional file 5: Figure S4A). Next, we analysed
the relative methylation differences between cancer and
normal sample pairs (i.e. differences between LNCaP
and PrEC, and between CAF and NPF cells), with CpG
methylation averaged across each amplicon. We ob-
served improved concordance in relative methylation
difference (compared to absolute methylation values) be-
tween WGBS and MBPS (Fig. 5), with highly significant
correlations of LNCaP–PrEC: r = 0.93, p < 2.2e−16;
CAF–NPF: r = 0.94, p < 2.2e−16 (Additional file 5: Figure
S4B). This indicates that the MBPS assay is able to ac-
curately replicate the DNA methylation differences be-
tween cell types as measured by discovery phase WGBS
data (Fig. 5).
Performance of multiplex bisulphite PCR sequencing on
FFPET DNA
As clinical samples are often preserved as FFPET, we
assessed the potential clinical utility of the MBPS by
evaluating its performance on DNA isolated from
FFPET. We performed the MBPS assay on 16 normal
and 30 breast tumour FFPET DNA samples (~ 10–20
ng) using the breast cancer panels with previously opti-
mised primer conditions (10 μM, 56 °C cycling
temperature). Following PCR amplification, clean-up
and library preparation, adequate amounts of sequencing
libraries were produced, at the correct sizes with min-
imal primer dimer products (Fig. 6a; Additional file 6:
Figure S5A). The libraries were then sequenced with
coverage all above 100 reads (Fig. 6b). We consistently
observe, across all amplicons, a clear and significant sep-
aration between lowly methylated normal and highly
methylated tumour DNA (Fig. 6c), similar to differences
observed in the original discovery study [25]. Together,
this provides a technical validation of the MBPS assay
for FFPET DNA.
Performance of multiplex bisulphite PCR sequencing on
circulating cell-free DNA
With the rapidly growing focus on the clinical utility of
liquid biopsy monitoring, we assessed the performance
of the breast cancer MBPS assay on circulating cfDNA.
We used the breast cancer panels with previously opti-
mised PCR conditions (10 μM PCR primer and 56 °C)
and performed the MBPS assay on n = 24 tumour
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cfDNA samples using ~ 1–5 ng of input cfDNA. Despite
the limited amount of input DNA, we observed robust
PCR amplification (15 cycles PCR) of all cfDNA samples
(Fig. 7a). After PCR amplification and clean-up, libraries
were prepared, quantitated and sequenced on the Next-
Seq500 (Additional file 6: Figure S5B). The sequencing
data revealed a wide range of sequencing reads across the
33 PCR amplicons, with coverage ranging from an average
of 78,000 to a maximum of 638,000 reads (Fig. 7b). We
were also able to measure DNA methylation levels in all
amplicons in the tumour cfDNA, as shown in Fig. 7c. This
data highlights the capability of the MBPS assay to detect
methylation levels in liquid biopsy samples and its poten-
tial utility for monitoring epigenetic biomarkers in clinical
samples.
Use of multiplex bisulphite PCR sequencing to assess
epigenetic heterogeneity
Another advantage of a targeted MBPS assay is the abil-
ity to discern the frequency of different DNA methyla-
tion patterns within each amplicon. This is informative
to investigate the intra-molecular methylation
Fig. 4 Technical sensitivity and coverage. Sensitivity of the MBPS assay was assessed using methylated-control DNA at 0%, 1% and 5% expected
levels of methylation, across three separate sequencing runs. Two representative amplicons (amplicons 44 and 55) are shown. Observed
methylation (%) (y-axis) is plotted against expected methylation (%) (x-axis). a Both representative amplicons show statistically significant
detection of both 1% and 5% methylation. b, c Down-sampling sequencing coverage at 100x, 1000x, 10,000x and 100,000x shows that the
sensitivity of detection of methylation improves with increased coverage. 1000x coverage and greater enables detection of 1% methylation that
is statistically significant. ns = not significant (p≥ 0.05), * = 0.01≤ p < 0.05, ** = 0.001≤ p < 0.01, *** = 0.0001≤ p < 0.001
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heterogeneity differences between samples, for example,
whether the methylation patterns in the target regions of
interest indicate a difference in cellular composition be-
tween samples [30]. Figure 8 shows the different methyla-
tion patterns observed across 4 CpG sites of a
representative amplicon (amplicon 36) in the prostate can-
cer panel in each of 4 cell types: (A) LNCaP, (B) CAF, (C)
NPF and (D) PrEC. For example, Fig. 8a shows that for
LNCaP, amplicon 36, we observe no methylation across
all 4 CpG sites in 96.18% of reads, whereas the frequency
of mosaic methylation patterns varies from 0.00003 to
1.68% of reads, giving an overall average methylation of
0.97%. In contrast, there is a large difference in average
methylation levels between CAF (49.91%) and NPF cells
(89.47%) for amplicon 36. Figure 8b and c show that the
reduction in average methylation observed between the
NPF cells and the matched CAF cells is driven by an in-
creased frequency of different mosaic methylation patterns
(seven patterns occur with > 5% frequency in the CAF),
rather than the takeover of a specific clonal DNA methyla-
tion pattern.
Discussion
There is widespread interest in DNA methylation as a
molecular biomarker in disease and cancer, with several
advantages that qualify DNA methylation for broad use
in clinical diagnostics: (1) DNA methylation is cell-type
specific, (2) it is a stable mark on DNA over cell division,
Fig. 5 Cross-platform comparison of multiplex bisulphite PCR method and whole-genome bisulphite sequencing methylation data. Barplot shows
the difference in methylation between a LNCaP and PrEC and b CAF and NPF for the prostate cancer panels, as measured by WGBS (orange
bars) and MBPS (purple bars). The methylation data between the two platforms shows good concordance in determining methylation
differences. c, d Representative examples of prostate DMRs corresponding to amplicon 1 (c) and amplicon 32 (d) showing WGBS and multiplex
data for each cell line: LNCaP (light pink), PrEC (light green), LNCaP-PrEC (dark blue), CAF (violet), NPF (light brown) and CAF-NPF (light blue). The
height of each bar represents the percentage of DNA methylation at each CpG site across the amplicon region
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(3) the patterns of methylation are faithfully retained
during long-term storage as fresh-frozen or FFPET sam-
ples and (4) the methodology to assay DNA methylation
biomarkers is already present in many clinical laborator-
ies, as the assays are similar to those in use for DNA-
sequence-based biomarkers. Previously, a landmark
study compared all methods for DNA methylation ana-
lysis compatible with routine clinical use and concluded
that targeted (locus-specific) bisulphite PCR sequencing
and pyrosequencing had the ‘best all-round performance’
for biomarker development and clinical diagnosis [22].
Amplicon bisulphite sequencing has been further
advanced through ‘multiplexing’ of the primers for sim-
ultaneous interrogation of multiple DNA methylated re-
gions in clinical samples, a critical improvement for an
assay where clinical material is very limited [23].
In this paper, we describe an updated protocol for tar-
geted multiplex bisulphite PCR sequencing, highlight
new optimisation steps to enhance its features and utility
and conduct a comprehensive evaluation of its perform-
ance. We show that pre- and post-sequencing optimisa-
tion improves the performance of this MBPS assay. Pre-
sequencing optimisation of PCR conditions such as
temperature, primer concentration and DNA input
Fig. 6 Multiplex bisulphite PCR amplicon sequencing of bisulphite-treated FFPET clinical DNA. a TapeStation gel showing 6 representative
sequencing libraries from breast cancer FFPET-derived DNA samples are the correct sizes (~ 250 bp). EL = electronic ladder is shown. b Boxplot
showing full coverage (top panel) across the 33 amplicons of the breast cancer panels from a sequencing run on our normal and tumour FFPET
samples. Bottom panel shows the same data with a different y-axis scale to better show the difference between the lower coverage amplicons,
with the dashed line indicating the cut-off (100 reads). c Line plots showing methylation data of 4 representative amplicons across 5 normal and
5 tumour clinical FFPET samples, demonstrating distinct separation between the methylation of normal and tumour samples
Fig. 7 Analysis of circulating cell-free tumour DNA using multiplex PCR bisulphite sequencing. a Gel showing successful MBPS libraries (~ 250 bp)
of 24 breast cancer-derived circulating cfDNA samples (pre-PCR cleanup). L = ladder. b Boxplot showing full coverage (top panel) across the 33
amplicons of the breast cancer panels from a sequencing run on the 24 cfDNA tumour samples. Bottom panel shows the same data with a
different y-axis scale to better show the difference between the lower coverage amplicons, with the dashed line indicating the cut-off (100 reads).
c Boxplot of the methylation values detected using the MBPS assay across 24 cfDNA samples
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achieves a balance between robust PCR yield and min-
imal primer dimer formation. Post-sequencing poorly
performing individual amplicons can be rescued, either
by creating a new ‘sub-panel’ or adjusting the concentra-
tions of individual primers to equalise the coverage be-
tween the amplicons.
Methylated and unmethylated regions have different
nucleotide sequence compositions after bisulphite con-
version which means that, for some regions, there may
be preferential amplification of either the unmethylated
(T-rich) or methylated (C-rich) sequence. Amplification
bias towards a particular sequence will significantly
affect the accuracy of methylation quantification [28]. It
is therefore important to include a gradient of quantita-
tive methylated-control DNA samples, to detect and cor-
rect PCR bias by comparing the expected to the
observed levels of methylation. We used a previously
published formula [28, 29] to quantify each amplicon in
the MBPS prostate cancer panels, identify PCR bias in
some amplicons and correct bias prior to downstream
analysis. These steps are important because PCR bias
has been largely overlooked in current targeted
Fig. 8 Epigenetic heterogeneity across different amplicons and samples. Matrix plot showing the read-level methylation sequencing data of each
CpG dinucleotide across a candidate amplicon (amplicon 36, prostate panel) with 4 CpG sites, in each of the 4 cell types: a LNCaP, b CAF, c NPF
and d PrEC. C denotes methylated cytosine; T denotes unmethylated cytosine. Barplots show the percentage frequency and number of reads of
each methylation pattern
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bisulphite PCR methodologies, and so inaccurate methy-
lation level measurements can affect the analysis and in-
terpretation of the results.
We conducted a range of technical experiments to
evaluate the performance of the updated MBPS protocol.
We compared MBPS and whole-genome bisulphite se-
quencing data and found a significant correlation of ab-
solute methylation values. However, there was not
complete concordance. This is likely due to the low se-
quencing coverage of the WGBS data (genome-wide se-
quencing coverage > 7X for CAF and NPF and > 20X for
LNCaP and PrEC, compared to an average of 68,000
reads in our prostate multiplex panel). Interestingly, we
show that the correlation between MBPS and WGBS
was stronger for measuring relative methylation differ-
ence between samples than absolute methylation values,
suggesting that any between-platform measurement dif-
ferences are uniform across all samples.
Using the methylated-control DNA samples, we also
evaluated the sensitivity of the assay. We show that we
can accurately detect differences in methylation between
0%, 1% and 5% methylation. Through down-sampling
sequencing coverage, we can detect 1% methylation dif-
ferences with as a little as 1000x coverage. Other ap-
proaches, such as methylation-specific PCR methods
(MSP-PCR), can also detect low levels of methylation
down to 0.1% [31, 32]; however, it is important to note
that these approaches do not assess the methylation of
individual CpG sites in the amplicon and are limited to
single amplicons rather than the multiple regions simul-
taneously targeted by a multiplex assay. As well as de-
tecting small changes in DNA methylation averaged
across a population of cells, targeted MBPS also allows
the assessment of heterogeneous DNA methylation pat-
terns within cell populations. Detection of subtle
changes in epigenetic profiles, for example, between nor-
mal and cancer cells, promises to reveal rare cell popula-
tions by detailing changes in different levels of cell type-
specific mosaic methylation patterns [30, 33].
A key strength of the MBPS assay is the generation of
high-quality next-generation sequencing data on very
low-input archival and fragmented FFPET DNA (5 ng)
which is important for validation and retrospective
screening studies. Further, the MBPS assay can measure
cfDNA methylation. This is of great clinical interest as
cfDNA in human blood can serve as a liquid biopsy to
provide a minimally invasive method for predictive and
prognostic marker detection [34]. Levels of cfDNA are
generally very low, ranging from ~ 0 to 50 ng/ml blood,
and the isolated cfDNA is commonly ~ 170–300 bp,
mostly corresponding to ~ 170 bp mono-nucleosomal
and ~ 300 bp di-nucleosomal DNA fragments. Here, we
show that minimal cfDNA (~ 1–5 ng) can generate high-
quality sequencing libraries to evaluate DNA
methylation, highlighting the potential utility of this ap-
proach for serial liquid biopsy monitoring of response to
therapy and disease relapse.
Other notable advantages of MBPS are that it is scal-
able in terms of numbers of samples, easily adjustable in
number of regions examined and has high reproducibil-
ity. It should be noted that another targeted bisulphite
sequencing method, which uses molecular-inversion
(padlock) probes, demonstrates greater multiplex scal-
ability and is able to target thousands, rather than hun-
dreds, of genomic regions [35, 36]. Similar to MBPS, this
method can also be performed on low DNA input, such
as 10–15 ng cfDNA starting material for biomarker de-
velopment [36]. However, a comparison between ampli-
con bisulphite sequencing methods (like MBPS) and the
padlock approach showed a lower percentage of reads
passing quality control and lower number of mapped
target regions in the padlock approach compared to the
100% success from amplicon bisulphite sequencing [22].
There are commercially available platforms for tar-
geted methylation profiling, such as methyl-capture se-
quencing [37, 38] and microfluidics-based Fluid Access
Array System [39]. However, both these methodologies
require high-quality, high-input DNA amounts (methyl-
capture seq 500 ng–3 μg; Fluid Access Array 50 ng), and
thus are ill-suited to working with limited clinical sam-
ples [23]. Methyl-capture sequencing platforms offer the
ability to design customizable panels to regions of clin-
ical interest, as well as pre-designed panels (up to 5 mil-
lion CpGs) [37, 38]. This extensive genomic coverage
makes this method well-suited for profiling large regions
of the epigenome and is thus good for biomarker discov-
ery. However, it is not the preferred option for bio-
marker validation because it is less sensitive in detecting
small effect sizes (5–10%) [38] and would require re-
synthesis of the capture pool when adjusting the number
of targets, such as for when drop-outs occur, which indi-
cates a more time-consuming and costly technique. Fur-
thermore, capture-based methods are unable to capture
very lowly represented molecules, compared to PCR-
based methods which can amplify all molecules includ-
ing heterogeneously methylated molecules [40]. Thus,
MBPS offers a method with higher sensitivity, cheaper
costs and faster turnaround times.
One limitation of MBPS, and for the aforementioned
capture- and microfluidic-based platforms, is that they
all rely on the process of bisulphite conversion. This is a
harsh chemical treatment that degrades and damages
DNA, which can lead to the generation of libraries with
low complexity and thus sequencing biases [41, 42]. This
is not ideal for working with clinically derived DNA
which can already be degraded and low yield. Recently,
new techniques have been developed to address this
problem, such as TET-assisted pyridine borane
Lam et al. Clinical Epigenetics           (2020) 12:90 Page 11 of 16
sequencing (TAPS) [43] and enzymatic methyl-
sequencing (EM-seq) [44]. These methods both rely on
TET enzymatic reactions to deaminate methylated cyto-
sines. Unlike bisulphite conversion, this reaction occurs
on double-stranded DNA, which preserves DNA integ-
rity and thus allows the generation of high-quality se-
quencing data from low-input amounts (TAPS 1 ng
gDNA/cfDNA; EM-seq 100 pg gDNA). This is highly ad-
vantageous for working with clinical material, although
thus far, these promising techniques have only been ap-
plied to epigenome-wide profiling, as an alternative to
WGBS, suitable for biomarker discovery. In the future,
these bisulphite-free approaches could be combined with
targeted multiplex methods, such as the multiplex PCR
sequencing approach presented in this study, for even
more sensitive and accurate biomarker validation, and
thus accelerated clinical translation.
In summary, the MBPS assay can evaluate DNA
methylation levels of individual CpG sites across mul-
tiple regions simultaneously including from FFPET DNA
and cfDNA. Overall, the MBPS assay provides a promis-
ing approach for assessing DNA methylation in clinical
samples, with potential applications in validation studies,
biomarker development and clinical diagnostics, includ-
ing prospective blood-based monitoring of patients.
Material and methods
DNA samples and extraction
DNA was extracted from LNCaP, PrEC, CAF and NPF
prostate cells as described in Pidsley et al. [24]. DNA
from clinical FFPET samples was extracted using the
QIAamp DNA FFPET Tissue Kit (Qiagen, Cat. No.
56404), and cfDNA (Bellberry Ethics Application 2015-
12-817-PRE-4) was extracted from plasma using
QIAamp Circulating Nucleic Acid Kit (Qiagen, Cat. No.
55114), according to the manufacturer’s protocol. ‘Test’
DNA used was human genomic blood DNA (Roche Cat.
No. 11691112001). Extracted DNA was quantified with
the Qubit dsDNA HS Assay Kit (Life Technologies,
USA). DNA was stored at − 20 °C until use.
Methylated-control DNA samples
Methylated-control DNA samples were prepared by
mixing 0% and 100% methylated DNA, commercially
sourced from Zymo (whole-genome-amplified (WGA)
non-methylated and methylated DNA, Cat. No. D5013),
in the proportions needed to produce the respective
methylated control. These methylated controls were in-
cluded in each sequencing run to assess both PCR bias
(e.g. 0%, 10%, 25%, 50%, 75%, 90%, 100%) and sensitivity
(e.g. 0%, 1%, 5%). Accurate quantitation of WGA meth-
ylated and non-methylated DNA was performed by
qPCR using 4–6 candidate gene regions under standard
PCR conditions.
Multiplex bisulphite PCR sequencing protocol
Figure 1 outlines the major steps in the multiplex bisul-
phite PCR sequencing protocol (as described below)—a
more detailed version is provided in the supplementary
information (Additional file 1: Figure S1) and our step-
by-step protocol (Additional file 2: step-by-step
protocol).
Primer design
Multiplex primers were designed using the custom
multiplex-specific primer design software, PrimerSuite
(www.primer-suite.com) [26, 45] which was adapted to
use the PrimerROC software to determine the optimal
PCR assay design parameters which would eliminate pri-
mer dimer artefacts when performing multiplex amplifi-
cation [45]. In brief, PrimerROC was used to first
determine the optimal free-energy cut-off for the multi-
plex assay to minimize dimer formation, which was then
applied as a filter to the multiplex assay design. As Pri-
merRoc is now available publically (http://www.primer-
dimer.com/roc/), this can be applied to any multiplex
panel designed through PrimerSuite. Next, an additional,
multiplex-specific DNA base-pairing heuristic was uti-
lised to predict in silico which PCR assays need to be re-
moved due to the likelihood that they would cause
primer-primer interactions; previously, the software re-
quired users to perform each singleplex assay using
quantitative PCR to determine its relative efficiency and
then use the PrimerPlex module to pool assays together.
PrimerSuite was then run with the following parameters:
oligo melting temperature of 54 °C, sodium concentra-
tion of 50 mM and maximum of 1 CpG allowed within
primers. Where there was a CpG site in the primer se-
quence, we substituted the cytosine with a Y/R base to
limit bias. Amplicon sizes were set between 105 and 150
bp for FFPET DNA samples and between 100 and 130
bp for circulating cfDNA samples. For prostate cell lines,
primers were designed for differentially methylated re-
gions described in Pidsley et al. [24], resulting in two
multiplex panels covering a total of 63 regions. For
breast cancer FFPET and cfDNA samples, primers were
designed for breast cancer-associated regions described
in Stirzaker et al. [25], resulting in two multiplex panels
covering 33 regions. Following primer design, we com-
pared the primer sequences with dbSNP data in UCSC
Genome Browser to confirm that they did not overlap
any common SNPs and advise that other users of Pri-
merSuite do the same.
Bisulphite conversion
Bisulphite conversion was performed using the EZ DNA
Methylation-Lightning Kit (Zymo Research, USA, Cat.
No. D5030 and D5033) according to the manufacturer’s
instructions. Based on the available material, as well as
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minimum DNA input needed, approximately 1–100 ng
of each sample was bisulphite converted. For FFPET
DNA samples, 2 μl of 10x bisulphite DNA lysis buffer
(10 mg/ml tRNA (20 μg/ml final), 20 mg/ml Proteinase K
(2.8 mg/ml final), 20% SDS (10% final)) was added to
18 μl of the starting DNA material and incubated at
55 °C for 1 h, before proceeding to the kit. For cfDNA
samples, approximately 1–5 ng of each sample was dir-
ectly bisulphite converted using the EZ DNA
Methylation-Lightning Kit (Zymo Research, USA, Cat.
No. D5030 and D5033) according to the manufacturer’s
instructions.
Optimisation of multiplex primers
Designed primers (ordered from Integrated DNA Tech-
nologies) were first individually diluted to 100 μM with
ultrapure water according to instructions given. Equal
volumes of forward and reverse primers, per primer pair,
were combined to dilute to a final concentration of
20 μM each. We first ran singleplex PCRs with all indi-
vidual primer pairs on test DNA and no-template con-
trol. PCR reactions for the amplification of bisulphite-
converted DNA had the following components (final
volume = 10 μl): 5X Promega GoTaq Flexi Buffer (2 μl,
Cat. No. M891A), CES 5X (1 μl, refer to Ralser et al.
2006 for CES recipe [46]), 25 mM MgCl2 (2 μl), 1 M
TMAC (0.15 μl, tetramethylammonium chloride solu-
tion, Sigma, Cat. No. T3411-500ML), dNTPs (0.1 μl, 10
mM each), primers (1 μl, forward and reverse at 2 μM
each), 5 U/μl Promega GoTaq Hot Start Polymerase
(0.04 μl, Cat. No. M500B) and DNA (1 μl, 10 ng/μl for
optimisation PCRs). The PCR cycling conditions were
94 °C, 7 min; 40 cycles (94 °C, 20 s; 55–57 °C, 30 s; 72 °C,
2 min); 72 °C, 5 min; 4 °C hold. PCR products were run
on a 2% agarose (with TAE buffer) gel electrophoresis to
check the specificity of each individual primer pair and
ensure bands at the correct size (according to Primer-
Suite design) and minimal primer dimer formation.
Should any individual PCR fail (very faint or no bands),
we recommend that these primers are discarded and
new primers designed for these regions.
Following singleplex PCR, equal amount of each pri-
mer pair was then pooled into their respective panels,
based on the results of the PrimerSuite software. Multi-
plex PCR reactions (see Additional file 2: section 2.3.3)
for reaction mix and cycling conditions were performed
at varying cycling temperatures (e.g. 55–57 °C) and pri-
mer concentrations (e.g. 20 μM, 10 μM, 5 μM, 2.5 μM) to
optimise these components. The optimal temperature
and primer concentration yielded the most product with
minimal primer dimers, as visualized by gel electrophor-
esis. These optimal conditions were used in all subse-
quent steps. As low DNA yield may result from working
with patient clinical samples, additional multiplex PCRs
were performed with varying levels of DNA input (e.g.
10 ng, 5 ng, 2.5 ng, 1.25 ng, 0.625 ng) to assess the min-
imal amount of DNA that these multiplex primers re-
quired for optimal amplification (see Additional file 2:
section 2.3.4).
Phosphorylation of primers and multiplex bisulphite PCRs
Following optimisation, the multiplex pooled primers
were phosphorylated to assist in the ligation of Illumina
indexing adapters below. This was done using an in-
house recipe (Additional file 2: section 2.4.1). Starting
with twice the optimal concentration of pooled primers
(such that for a final concentration of 10 μM, start with
20 μM of pooled primers), the following mix was made
(final volume = 50 μl): pooled primers (37.5 μl), 10X NEB
DNA ligase buffer (2 μl, Cat. No. B0202S), T4 poly-
nucleotide kinase (2 μl, Cat. No. M0201L), 10 mM ATP
(5 μl, Cat. No. P0756S) and 1M DTT (0.25 μl, Thermo
Fisher, Cat No. P2325). This reaction was performed at
37 °C for an hour. The reaction was then topped up with
the following (final volume = 25 μl): 10X NEB ligase buf-
fer (2.5 μl), T4 polynucleotide kinase (1 μl), 10 mM ATP
(2.5 μl) and 1M DTT (0.25 μl). The reaction was per-
formed for another hour at 37 °C. The multiplex pooled
primers were then at the optimal concentration (e.g.
10 μM).
Using these phosphorylated pooled primers, multiplex
bisulphite PCRs were performed on bisulphite-treated
patient DNA, cell line DNA and methylated-controls, in
triplicate under optimised multiplex PCR conditions.
The PCRs were performed in 15 μl reactions with fol-
lowing components: 5X Promega GoTaq Flexi Buffer
(3 μl, Cat. No. M890A), CES 5X (1.5 μl), 25 mM MgCl2
(3 μl), 1M TMAC (0.225 μl), dNTPs (0.15 μl, 10 mM
each), phosphorylated primers (3 μl, at optimal concen-
tration e.g. 10 μM), 5 U/μl Promega GoTaq Hot Start
(0.06 μl) and DNA (2 μl). The PCR cycling conditions
were similar to above, using the optimal cycling
temperature as determined during the optimisation
steps, and only 28 cycles were performed here. The opti-
mal DNA final concentration is 0.5–1 ng/μl, subject to
availability of DNA material (see optimisation PCRs for
determination of minimum DNA input required). The
triplicate PCRs were pooled and PCR cleanup performed
using Agencourt AMPure XP beads (Cat. No. A63881)
at a 1:1.6 (up to 1:2) ratio (see Additional file 2: section
2.4.3 for clean-up procedure).
Library preparation
Following PCR clean-up, TruSeq Dual Index Adaptors
(Illumina, Part No. 15032317) were ligated to each sam-
ple. To each cleaned PCR product, 1:20 dilution
(0.75 μM) of adaptors and ligation mastermix (see
Additional file 2: section 2.5.1 for recipe) were added
Lam et al. Clinical Epigenetics           (2020) 12:90 Page 13 of 16
accordingly (final volume = 11.2 μl): cleaned PCR prod-
uct (7 μl), 0.75 μM adaptors (1 μl) and ligation master-
mix (3.2 μl), then incubated at 37 °C for 30 min. A
further round of 8–12 cycles of PCR (see above for cyc-
ling conditions) was performed to amplify the libraries
and incorporate the Illumina sequencing primers (P5 &
P7, TruSeq DNA Library Prep Kit HT). The reaction
mix was as follows (final volume = 40 μl): 5X Promega
GoTaq Flexi Buffer (8 μl), 25 mM MgCl2 (9.6 μl), dNTPs
(0.4 μl, 10 mM each), P5 and P7 primers (4 μl, 10 μM), 5
U/μl Promega GoTaq Hot Start Polymerase (0.25 μl) and
ligated DNA (5 μl). The libraries were then purified
using AMPure XP beads at a 1:1 ratio.
Following library purification, each library was quanti-
fied using the Qubit dsDNA HS Assay Kit (Life Tech-
nologies, USA). Representative libraries, including lowest
and highest concentration libraries, were checked on
TapeStation (D1000, Cat. No. 5067-5602 and 5067-
5582). One microliter of library mix with 3 μl buffer per
library was run on the TapeStation machine to check li-
brary size (~ 250 bp based on amplicon size plus sequen-
cing adaptors) and purity. The individual libraries were
then pooled at equal amounts (for each sequencing
run—96 samples) and the pooled libraries run on the
TapeStation. If primer dimer bands (< 200 bp) were ob-
served, a second clean-up (1:1 AMPure XP beads) was
performed, and the quantification steps above were re-
peated. The pooled libraries were then diluted to 10–20
nM according to further Qubit quantification. KAPA
qPCR (KAPA Library Quantification Kit (ABI Prism),
Roche, Cat. No. 07960204001) was then performed on
the pooled library, according to manufacturer’s instruc-
tions. The pooled library was then diluted to 10 nM ac-
cording to the KAPA qPCR results, ready for
sequencing.
Sequencing
Sequencing of the LNCaP, PrEC, CAF and NPF prostate
cells was performed on the Illumina MiSeq™ sequencer
(Illumina, CA, USA). Sequencing of the breast cancer
FFPET DNA and cfDNA samples was performed on the
Illumina NextSeq™ sequencer (Illumina, CA, USA).
Methylated controls were included in each sequencing
run. Sample preparation for sequencing on these ma-
chines was performed according to Illumina’s instruc-
tions, with library concentration and addition of PhiX
Control v3 (Illumina, FC-110-3001) optimised for the in-
dividual machines.
Data analysis/bioinformatics
Processing of multiplex sequencing data
We used the MethPanel workflow [27] to preprocess
and align reads from multiplex bisulphite sequencing to
pre-defined regions of the reference genome hg19 build
(defined using the genomic co-ordinates for each ampli-
con from the output from the PrimerSuite software).
Specifically, FASTQ files were trimmed to produce high-
quality reads with base quality ≥ 30 and read length ≥ 20
bp and to clip 1 bp from both reads (https://github.com/
FelixKrueger/TrimGalore). Non-conversion of non-CpG
cytosines was used to estimate bisulphite conversion rate
(typically > 99.4%). Bismark version 0.22.3 [47] was used
to map these trimmed reads to the pre-defined reference
genome, allowing 1 non-bisulphite mismatch per read,
with all other parameters kept to their default values. Se-
quencing metrics for all runs in this study are summa-
rized in Additional file 7: Supplementary Table 1. For
each bam file produced by Bismark, MethPanel [27] was
used to perform calculation of DNA methylation levels
and merge all samples into a single table. Further quality
control was performed to remove amplicons and sam-
ples with < 100X coverage from the methylation table.
All downstream analysis and data visualization were
conducted using MethPanel or custom scripts in R (ver-
sion ≥ 3.2.2) [48]. For results where we present a single
methylation value for an amplicon, this value was de-
rived by taking the mean methylation of all CpG sites in
an amplicon for each sample.
Whole-genome bisulphite sequencing data
For CAF and NPF methylation, we used in-house WGBS
data that was generated and processed as previously de-
scribed [24]. All raw and processed data are publically
available at NCBI Gene Expression Omnibus (GEO)
(www.ncbi.nlm.nih.gov/geo) under accession number
GSE86260, sample names: WGBS CAF2 and WGBS
NPF2.
For LNCaP and PrEC methylation, we used in-house
WGBS data that was generated and processed as previ-
ously described [19]. All raw and processed data are
publically available at NCBI GEO (www.ncbi.nlm.nih.
gov/geo) under accession number GSE86832.
To allow comparison of WGBS data with multiplex
data, we created a bed-formatted file of the 158 CpG
sites covered by the multiplex panel and applied the ‘get-
Meth’ function in the bsseq package in R to extract
WGBS data at these sites.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13148-020-00880-y.
Additional file 1: Figure S1. Detailed flow diagram of multiplex PCR
bisulphite sequencing assay.
Additional file 2: Step-by-step protocol (Word Document)
Additional file 3: Figure S2. Pre-sequencing optimisation of multiplex
PCR primers - Prostate Cancer panels (PDF). (A) PCR products of single-
plex amplification of 63 individual primer pairs from the prostate cancer
panels run on 2% agarose gel. The gel shows the specificity of all the
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primer pairs and PCR products of the correct size (105-150 bp) with
minimal primer dimer formation. (-) no template; (+) bisulphite-treated
test DNA template (10ng), (L) 100 bp DNA Ladder. (B) Singleplex primers
were pooled into their respective multiplex panels and the success of
multiplex PCR reactions is shown at different primer concentrations (20
μM, 10 μM, 5 μM and 1 μM) and at an annealing temperature of 56 °C.
(C) PCR products from the multiplex panel testing DNA input amounts
from 10 ng, 5 ng, 2.5 ng, 1.25 ng of bisulphite-treated control DNA; (+)
test DNA; (-) no template control.
Additional file 4: Figure S3. Technical Sensitivity and Coverage (PDF).
Sensitivity of the multiplex PCR bisulphite sequencing assay was assessed
using methylated-control DNA at 0%, 1% and 5% expected levels of
methylation, across three separate sequencing runs. Three representative
amplicons are shown. Observed methylation (%) (y-axis) is plotted against
expected methylation (%) (x-axis). Down-sampling sequencing coverage
at 100x, 1,000x, 10,000x and 100,000x shows that the sensitivity of
detection of methylation improves with increased coverage.
Additional file 5: Figure S4. Platform comparison of MBPS and WGBS
methylation data (PDF). (A) Correlation plots of absolute methylation
levels of each CpG in the prostate cancer panels, as measured by
multiplex bisulphite PCR (y-axis) and WGBS (x-axis), across each of the
four cells (LNCaP, PrEC, CAF, NPF). (B) Correlation plots of relative
methylation differences (LNCaP minus PrEC; CAF minus NPF cells) as
measured by MBPS (y-axis) and WGBS (x-axis). Pearson’s correlation test
was used to derive the correlation coefficient (r) and p-value (p).
Additional file 6: Figure S5. MBPS of bisulphite-treated FFPET clinical
DNA (PDF). Tape Station electropherogram showing representative se-
quencing libraries from breast cancer (A) FFPET-derived DNA samples
and (B) circulating cell-free DNA samples. The grey peak at ~250 bp rep-
resents the library (amplicon + sequencing adaptors), with peaks ob-
served < 200 bp representing residual primer dimers.
Additional file 7: Table S1.
Abbreviations
CAF: Cancer-associated fibroblasts; cfDNA: Circulating cell-free DNA;
DMRs: Differentially methylated regions; FFPET: Formalin-fixed paraffin-
embedded tissue; LNCaP: Prostate cancer epithelial cell line; MBPS: Multiplex
bisulphite PCR sequencing; NPF: Non-malignant prostate fibroblasts;
PrEC: Normal human prostate epithelial cells; WGA: Whole-genome
amplified; WGBS: Whole-genome bisulphite sequencing
Acknowledgements
This work is supported by the National Health and Medical Research Council
(NHMRC) project grant (1106870 - SJC, GPR, RP, MGL) and fellowships
(1063559 and 1156408 - SJC; 1002648 and 1102752 - GPR), Cancer Australia
(1044458 - GPR), National Breast Cancer Foundation IIRS Grant (IIRS-18-137 -
CS), National Foundation and Medical Research and Innovation grant
(NFMRI) (CS), Cancer Council NSW (RG-18-09 - RP, SJC) and the Victorian
Government through the Victorian Cancer Agency (Fellowship MCRF18017
-MGL). Computational resources were provided by the Australian
Government through NCI Raijin under the National Computational Merit
Allocation Scheme 2019, project wk73 (SJC, PLL)
Authors’ contributions
RP, CS and SJC coordinated the overall study and wrote the manuscript
together with DL. DL, JS and WQ performed the experiments, including
multiplex PCR optimisations, bisulphite treatment of DNA, library preparation
and sequencing. PLL, DL and RP analysed the data. JL and DK designed the
multiplex PCR primers. GPR and MGL supplied fibroblast DNA samples. MT
and DK supplied tumour cfDNA samples. All authors have read and
approved the final manuscript.
Availability of data and materials
The datasets generated and analysed during the current study are available
from the corresponding authors on reasonable request.
The WGBS data (raw and processed) analysed during this study is publically
available at NCBI GEO (www.ncbi.nlm.nih.gov/geo) under accession numbers
GSE86260 (CAF and NPF) and GSE86832 (LNCaP and PrEC).
Ethics approval and consent to participate
cfDNA samples for this study were obtained with ethical approval from the
Bellberry Human Research Ethics Committee (Application 2015-12-817-PRE-4).
Patient samples for primary fibroblasts were obtained with written informed
consent with human ethics approval from Monash University (2004/145) and
Cabrini Hospital (03-14-04-08). Human tissue samples representing normal
and tumour breast from formalin-fixed paraffin-embedded tissue were as
described in Stirzaker et al. 2015 [25]. The study protocol was approved by
the Hunter New England Research Ethics Committee (NSW HREC reference
no.: HREC/09/HNE/153), Newcastle, New South Wales and Princess Alexandra





The authors declare that they have no competing interests.
Author details
1Epigenetics Research Laboratory, Genomics and Epigenetics Division, Garvan
Institute of Medical Research, Sydney, New South Wales 2010, Australia. 2St
Vincent’s Clinical School, UNSW Sydney, Sydney, New South Wales 2010,
Australia. 3Monash Partners Comprehensive Cancer Consortium, Monash
Biomedicine Discovery Institute Cancer Program, Prostate Cancer Research
Group, Department of Anatomy and Developmental Biology, Monash
University, Clayton, VIC 3800, Australia. 4Cancer Research Division, Peter
MacCallum Cancer Centre, Melbourne, VIC 3000, Australia. 5Sir Peter
MacCallum Department of Oncology, The University of Melbourne, Parkville,
VIC 3010, Australia. 6Centre for Personalised Nanomedicine, Australian
Institute for Bioengineering and Nanotechnology (AIBN), The University of
Queensland, St Lucia, Queensland 4072, Australia.
Received: 18 February 2020 Accepted: 4 June 2020
References
1. Bird AP. CpG-rich islands and the function of DNA methylation. Nature.
1986;321(6067):209–13.
2. Jones PA. Functions of DNA methylation: islands, start sites, gene bodies
and beyond. Nat Rev Genet. 2012;13(7):484–92.
3. Feil R, Fraga MF. Epigenetics and the environment: emerging patterns and
implications. Nat Rev Genet. 2012;13(2):97–109.
4. Martin EM, Fry RC. Environmental influences on the epigenome: exposure-
associated DNA methylation in human populations. Annu Rev Public
Health. 2018;39:309–33.
5. Feinberg AP. Phenotypic plasticity and the epigenetics of human disease.
Nature. 2007;447(7143):433–40.
6. Baylin SB, Jones PA. A decade of exploring the cancer epigenome -
biological and translational implications. Nat Rev Cancer. 2011;11(10):726–34.
7. Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128(4):683–92.
8. Baylin SB, Jones PA. Epigenetic determinants of cancer. Cold Spring Harb
Perspect Biol. 2016;8(9).
9. Cancer Genome Atlas N. Comprehensive molecular portraits of human
breast tumours. Nature. 2012;490(7418):61–70.
10. Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian
carcinoma. Nature. 2011;474(7353):609–15.
11. International Cancer Genome C, Hudson TJ, Anderson W, Artez A, Barker
AD, Bell C, et al. International network of cancer genome projects. Nature.
2010;464(7291):993–8.
12. Kristensen LS, Hansen LL. PCR-based methods for detecting single-locus
DNA methylation biomarkers in cancer diagnostics, prognostics, and
response to treatment. Clin Chem. 2009;55(8):1471–83.
13. Mikeska T, Bock C, Do H, Dobrovic A. DNA methylation biomarkers in
cancer: progress towards clinical implementation. Expert Rev Mol Diagn.
2012;12(5):473–87.
14. Umer M, Herceg Z. Deciphering the epigenetic code: an overview of DNA
methylation analysis methods. Antioxid Redox Signal. 2013;18(15):1972–86.
15. Lister R, Pelizzola M, Dowen RH, Hawkins RD, Hon G, Tonti-Filippini J, et al.
Human DNA methylomes at base resolution show widespread epigenomic
differences. Nature. 2009;462(7271):315–22.
Lam et al. Clinical Epigenetics           (2020) 12:90 Page 15 of 16
16. Clark SJ, Harrison J, Paul CL, Frommer M. High sensitivity mapping of
methylated cytosines. Nucleic Acids Res. 1994;22(15):2990–7.
17. Lister R, O'Malley RC, Tonti-Filippini J, Gregory BD, Berry CC, Millar AH, et al.
Highly integrated single-base resolution maps of the epigenome in
Arabidopsis. Cell. 2008;133(3):523–36.
18. Nair SS, Luu PL, Qu W, Maddugoda M, Huschtscha L, Reddel R, et al.
Guidelines for whole genome bisulphite sequencing of intact and FFPET
DNA on the Illumina HiSeq X ten. Epigenetics Chromatin. 2018;11(1):24.
19. Pidsley R, Zotenko E, Peters TJ, Lawrence MG, Risbridger GP, Molloy P, et al.
Critical evaluation of the Illumina MethylationEPIC BeadChip microarray for
whole-genome DNA methylation profiling. Genome Biol. 2016;17(1):208.
20. Bibikova M, Le J, Barnes B, Saedinia-Melnyk S, Zhou L, Shen R, et al.
Genome-wide DNA methylation profiling using Infinium(R) assay.
Epigenomics. 2009;1(1):177–200.
21. Peters TJ, Buckley MJ, Statham AL, Pidsley R, Samaras K, Lord RV, et al. De
novo identification of differentially methylated regions in the human
genome. Epigenetics Chromatin. 2015;8:6.
22. BLUEPRINT consortium, Bock C, Halbritter F, Carmona FJ, Tierling S,
Datlinger P, Assenov Y, Berdasco M, et al. Quantitative comparison of DNA
methylation assays for biomarker development and clinical applications. Nat
Biotechnol. 2016;34(7):726–37.
23. Korbie D, Lin E, Wall D, Nair SS, Stirzaker C, Clark SJ, et al. Multiplex bisulfite
PCR resequencing of clinical FFPE DNA. Clin Epigenetics. 2015;7:28.
24. Pidsley R, Lawrence MG, Zotenko E, Niranjan B, Statham A, Song J, et al.
Enduring epigenetic landmarks define the cancer microenvironment.
Genome Res. 2018;28(5):625–38.
25. Stirzaker C, Zotenko E, Song JZ, Qu W, Nair SS, Locke WJ, et al. Methylome
sequencing in triple-negative breast cancer reveals distinct methylation
clusters with prognostic value. Nat Commun. 2015;6:5899.
26. Lu J, Johnston A, Berichon P, Ru KL, Korbie D, Trau M. PrimerSuite: a high-
throughput web-based primer design program for multiplex bisulfite PCR.
Sci Rep. 2017;7:41328.
27. Luu PL, Ong P-T, Loc TTH, Lam D, Pidsley R, Stirzaker C, et al. MethPanel: a
parallel pipeline and interactive analysis tool for multiplex bisulphite PCR
sequencing to assess DNA methylation biomarker panels for disease
detection. BioRxiv. 2020.
28. Warnecke PM, Stirzaker C, Melki JR, Millar DS, Paul CL, Clark SJ. Detection
and measurement of PCR bias in quantitative methylation analysis of
bisulphite-treated DNA. Nucleic Acids Res. 1997;25(21):4422–6.
29. Moskalev EA, Zavgorodnij MG, Majorova SP, Vorobjev IA, Jandaghi P, Bure
IV, et al. Correction of PCR-bias in quantitative DNA methylation studies by
means of cubic polynomial regression. Nucleic Acids Res. 2011;39(11):e77.
30. Landan G, Cohen NM, Mukamel Z, Bar A, Molchadsky A, Brosh R, et al.
Epigenetic polymorphism and the stochastic formation of differentially
methylated regions in normal and cancerous tissues. Nat Genet. 2012;
44(11):1207–14.
31. Cottrell SE, Laird PW. Sensitive detection of DNA methylation. Ann N Y Acad
Sci. 2003;983:120–30.
32. Rand KN, Ho T, Qu W, Mitchell SM, White R, Clark SJ, et al. Headloop
suppression PCR and its application to selective amplification of methylated
DNA sequences. Nucleic Acids Res. 2005;33(14):e127.
33. Barrett JE, Feber A, Herrero J, Tanic M, Wilson GA, Swanton C, et al.
Quantification of tumour evolution and heterogeneity via Bayesian epiallele
detection. BMC Bioinformatics. 2017;18(1):354.
34. Pidsley R, Stirzaker, C. Cancer methylation biomarkers in circulating cell-free
DNA. Hesson L. PA, editor. Singapore: Springer; 2019. 217-45 p.
35. Diep D, Plongthongkum N, Gore A, Fung HL, Shoemaker R, Zhang K.
Library-free methylation sequencing with bisulfite padlock probes. Nat
Methods. 2012;9(3):270–2.
36. Xu RH, Wei W, Krawczyk M, Wang W, Luo H, Flagg K, et al. Circulating
tumour DNA methylation markers for diagnosis and prognosis of
hepatocellular carcinoma. Nat Mater. 2017;16(11):1155–61.
37. Allum F, Shao X, Guenard F, Simon MM, Busche S, Caron M, et al.
Characterization of functional methylomes by next-generation capture
sequencing identifies novel disease-associated variants. Nat Commun. 2015;
6:7211.
38. Teh AL, Pan H, Lin X, Lim YI, Patro CP, Cheong CY, et al. Comparison of
methyl-capture sequencing vs. Infinium 450 K methylation array for
methylome analysis in clinical samples. Epigenetics. 2016;11(1):36–48.
39. Bourgon R, Lu S, Yan Y, Lackner MR, Wang W, Weigman V, et al. High-
throughput detection of clinically relevant mutations in archived tumor
samples by multiplexed PCR and next-generation sequencing. Clin Cancer
Res. 2014;20(8):2080–91.
40. Jiang J, Wolters JE, van Breda SG, Kleinjans JC, de Kok TM. Development of
novel tools for the in vitro investigation of drug-induced liver injury. Expert
Opin Drug Metab Toxicol. 2015;11(10):1523–37.
41. Tanaka K, Okamoto A. Degradation of DNA by bisulfite treatment. Bioorg
Med Chem Lett. 2007;17(7):1912–5.
42. Olova N, Krueger F, Andrews S, Oxley D, Berrens RV, Branco MR, et al.
Comparison of whole-genome bisulfite sequencing library preparation
strategies identifies sources of biases affecting DNA methylation data.
Genome Biol. 2018;19(1):33.
43. Liu Y, Siejka-Zielinska P, Velikova G, Bi Y, Yuan F, Tomkova M, et al. Bisulfite-
free direct detection of 5-methylcytosine and 5-hydroxymethylcytosine at
base resolution. Nat Biotechnol. 2019;37(4):424–9.
44. Vaisvila RP, V.K.C.; Sun, Z.; Langhorst, B.W.; Saleh, L.; Guan, S.; Dai, N.;
Campbell, M.A.; Sexton, B.S; Marks, K.; Samaranayake, M.; Samuelson, J.C.;
Church, H.E.; Tamanaha, E.; Corrêa Jr., I.R.; Pradhan, S.; Dimalanta, E.T.; Evans
Jr., T.C.; Williams, L.; Davis, T.B. EM-seq: detection of DNA methylation at
single base resolution from picograms of DNA. bioRxiv. 2019.
45. Johnston AD, Lu J, Ru KL, Korbie D, Trau M. PrimerROC: accurate condition-
independent dimer prediction using ROC analysis. Sci Rep. 2019;9(1):209.
46. Ralser M, Querfurth R, Warnatz HJ, Lehrach H, Yaspo ML, Krobitsch S. An
efficient and economic enhancer mix for PCR. Biochem Biophys Res
Commun. 2006;347(3):747–51.
47. Krueger F, Andrews SR. Bismark: a flexible aligner and methylation caller for
bisulfite-Seq applications. Bioinformatics. 2011;27(11):1571–2.
48. R Core Team: a language and environment for statistical computing. Vienna,
Austria: R Foundation for Statistical Computing; 2013.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Lam et al. Clinical Epigenetics           (2020) 12:90 Page 16 of 16
